This week’s money wasn’t chasing a category. It was underwriting the next step. Oryon raised after pairing fresh capital with early clinical data. Crossbow raised to finish a Phase I trial. Posh raised to move upmarket with bigger events and sturdier infrastructure. Grub Lab raised on a repeat-traffic wedge that restaurants can actually use. Even Persevere’s small seed worked because the use of funds was painfully specific. Different sectors. Same pattern. Investors moved when the before-and-after was easy to see.
If you’re raising now, stop trying to sell the whole future in a meeting. Sell the next unlock. One trial. One rollout. One customer tier. One behavior change. That’s a cleaner story than “big market, big vision” right now.
A lot of execution problems do not start in strategy. They start when the systems underneath hiring, onboarding, and day-to-day people ops are still held together by scattered files and manual processes, which is exactly what Deel’s first HR software implementation guide is built to help fix.
Your first HR system, implemented right
Rolling out your first HR tool? Get a step-by-step guide to avoid common mistakes, drive adoption, and build a scalable HR foundation.
Oryon paired fresh capital with visible proof
Oryon emerged from stealth with a new $21 million Series A tranche, bringing total financing to $42 million. It tied the raise to early Parkinson’s data showing motor improvements and neuroimaging evidence of restored dopaminergic signaling. That made the round feel less like a research bet and more like a progress bet. See full article.
What this means for your raise: The strongest rounds give investors a before-and-after they can see. If you have a milestone, wrap the raise around it. Don’t separate the money story from the proof story.
Posh Raises $37M in Series B Funding Round
Posh raised $37 million in a Series B led by FirstMark. The story here is clean: the company is using the capital to deepen the product, expand go-to-market, and support larger festivals and global organizers. That is a much stronger pitch than “we’re building community for events.” See full article.
What this means for your raise: Growth-stage founders should talk less about energy and more about expansion math. Show what gets bigger, what gets sturdier, and what new customer you can handle after the round.
Crossbow Therapeutics hits the target with $77m Series B funding
Crossbow Therapeutics closed a $77 million Series B to complete Phase I work on CBX-250 and advance its broader T-Bolt immunotherapy pipeline. The round was co-led by Taiho Ventures and Arkin Bio Capital, and the use of funds was explicit from the start. Investors knew exactly what progress they were paying for. See full article.
What this means for your raise: If the round is truly milestone-driven, say exactly what the money unlocks and by when. Investors back motion they can map.
Grub Lab raised on distribution and repeat visits
Grub Lab pulled in $6 million from Quantaco to expand a platform that helps independent restaurants use licensed sports and entertainment experiences to drive traffic, loyalty, and longer family stays. This is not a complicated story. Operators are under pressure, family traffic is more experience-driven, and the product is designed to move that number in a direction owners care about. See full article.
What this means for your raise: You don’t need a flashy market. You need a broken workflow, a painful incumbent, and a wedge that makes switching feel urgent.
Persevere showed how a small round can still sound serious
Persevere Therapeutics launched earlier this month and raised $1.5 million as part of an ongoing seed round to support ovarian cancer testing of a drug already in clinical development. That is why the raise matters. The amount is small, but the use of funds is sharp, and the asset is already further along than most new biotech startups. See full article.
What this means for your raise: A modest round can still land if the next experiment, customer proof point, or de-risking step is brutally specific. Small does not have to sound small. Vague does.
This-or-that: what’s the strongest “before-and-after” proof to wrap a raise around?
The best founders do not just explain what the money is for. They explain what becomes easier, faster, or more believable after the round closes.
Use this structure:
We’re raising $[X] to achieve [specific milestone] by [timeframe].
If we hit it, the company changes in three ways: [growth], [proof], and [optionality].
Example:
We’re raising $2.5M to reach $250K MRR and sign 3 enterprise customers in the next 12 months.
If we hit that, we prove repeatable demand, strengthen our next-round position, and expand with real leverage.
This works because it gives investors a cleaner way to think about the round. Not as money going into the business. As a clear step that changes the business.
That is what makes a raise feel easier to underwrite
Air Street Capital is worth knowing if you’re building an AI-first company and want a specialist who can write a meaningful first check. The firm announced Fund III at $232.3 million today and says it will lead early-stage rounds with checks from $500K to $15M, plus selective growth investments up to $25M. Air Street focuses on AI-first software, developer tools and infrastructure, techbio and science, autonomy, and defense-related systems, and its public materials highlight portfolio names like Synthesia, Profluent, Poolside, Wayve, Sereact, ElevenLabs, Lambda, and Crusoe.
Best path in is direct: Air Street’s own guidance says founders can email Nathan Benaich at [email protected] with a brief company description, the core AI capability, and the business stage.
The clearest pattern in the last 24 hours was simple: founders got funded when the next step was easy to underwrite. That is the bar right now. Not bigger language. Better visibility into what changes after the round. Reply with your opener or your raise memo, and I’ll tell you where the story gets tighter.
I'm Marcus Cole. I spent four years on the investor side at a $200M seed fund in New York, reviewing 800+ decks a year, sitting in partner meetings, watching founders win and lose at the table.
Then I crossed over. Raised $4.2M across two companies. One got acqui-hired after a $1.4M raise. The other raised $2.8M seed and is still running.
I've been in your seat and theirs. Capital Raise is what I wish I'd had while raising: straight talk, no waste, built for founders who are actually in it.
Disclaimer: Capital Raise is a newsletter for informational purposes only. Nothing in this newsletter constitutes investment advice, financial advice, or a solicitation to invest.
Always do your own due diligence. Consult a licensed financial advisor before making investment decisions.